Red Queen Bio is using AI to design antibodies for future viruses, WSJ says
Red Queen Bio, a biosecurity startup backed by OpenAI, has raised $36 million in total to design antibody drugs against viruses, including ones that AI systems could one day help create, The Wall Street Journal reported.
The company is starting with antibodies against bird flu and other influenza viruses and plans its first clinical trials in 2027, according to the Journal. It later wants to target coronaviruses, Ebola-like viruses and relatives of smallpox.
Design, test, repeat
Red Queen uses AI to design antibodies that bind tightly to viral targets. It grows cells to produce and test the candidates in the lab, then feeds the results back into its models to design better versions.
“The tighter they bind, the less of them you need,” chief executive Nikolai Eroshenko told the Journal. “Suddenly, you have something that can scale.”
Eroshenko and co-founder Hannu Rajaniemi spun the company out of HelixNano in 2025....
Copyright of this story solely belongs to thenextweb.com. To see the full text click HERE
